Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors while in the central nervous program, conolidine modulates alternate molecular targets. A Science Advancements review identified that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://actorq752uka8.life3dblog.com/profile